A biotin-avidin-system-based virus-mimicking nanovaccine for tumor immunotherapy

Virus is a nanosized pathogen and mainly composed of viral protein and nucleic acids. Under the pressure of long-term selection, mammals have gradually evolved effective immune mechanisms to defend themselves against viruses. In addition to recognizing viral proteins, immune system can also respond...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of controlled release 2021-04, Vol.332, p.245-259
Hauptverfasser: Lu, Zhuoxuan, Zhang, Yanwei, Wang, Yi, Tan, Guang-Hong, Huang, Feng-Ying, Cao, Rong, He, Nongyue, Zhang, Liming
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 259
container_issue
container_start_page 245
container_title Journal of controlled release
container_volume 332
creator Lu, Zhuoxuan
Zhang, Yanwei
Wang, Yi
Tan, Guang-Hong
Huang, Feng-Ying
Cao, Rong
He, Nongyue
Zhang, Liming
description Virus is a nanosized pathogen and mainly composed of viral protein and nucleic acids. Under the pressure of long-term selection, mammals have gradually evolved effective immune mechanisms to defend themselves against viruses. In addition to recognizing viral proteins, immune system can also respond to viral sequence-specific nucleic acids, including CpG ODN, single- and double- strand RNA, and thereby enhancing the ability to remove infected viruses. Inspired by these immune mechanisms, we have attempted to develop a tracing virus-mimicking nanovaccine for tumor immunotherapy. This nanovaccine mainly consists of nucleic acids (CpG ODN), proteins (including tumor-associated antigen, and neutravidin (nAvidin) as skeleton materials for constructing nanovaccine and carriers for loading tumor-associated antigen and CpG ODN), and the dye molecules for assembling nAvidin to form nanoparticles comparable in size to viruses and tracing the vaccine in vitro and in vivo. The as-prepared nanovaccine efficiently induces the maturation of dendritic cell, the enhancement of antigen cross-presentation ability, and amplification of cytokine production in vitro. Furthermore, in vivo analysis clearly shows that it targets lymph nodes, successfully presents antigens to generate tumor-antigen-specific CD8+ T cells and induces a Th1-biased immune response. Most notably, this virus-mimicking nanovaccine significantly inhibits the growth of antigen-expressed tumor and prolongs the survival time of the antigen-expressed tumor bearing mice. [Display omitted] •Nanovaccine formulation simulates viruses in composition and size.•Nanovaccine has self-tracing capability in vivo and in vitro.•Nanovaccine stimulates DC maturation and promotes antigen presentation.•Nanovaccine targets lymph nodes, stimulates generation of specific CD8+ T cells.•Nanovaccine inhibits tumor growth and prolongs survival of tumor-bearing mice.
doi_str_mv 10.1016/j.jconrel.2021.02.029
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2495401926</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168365921001024</els_id><sourcerecordid>2495401926</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-8f54b8d23c358ed6fb1d2944dd09a65c672cda9fa2a939ee39067d6cb8a42a393</originalsourceid><addsrcrecordid>eNqFkMtOwzAQRS0EouXxCaAs2aQ4tuPEK1QhXhISLGBtOfYEXGq72Eml_j2uWtgijeZuzsyduQhdVHhW4YpfL2YLHXyE5YxgUs0wySUO0LRqG1oyIepDNM1cW1Jeiwk6SWmBMa4pa47RhFLOGkbxFL3Oi86GwfpSra3JkjZpAFd2KoEp1jaOqXTWWf1l_UfhlQ9rpbX1UPQhFsPocrfOjT4MnxDVanOGjnq1THC-11P0fn_3dvtYPr88PN3On0udDxrKtq9Z1xpCNa1bMLzvKkMEY8ZgoXiteUO0UaJXRAkqAKjAvDFcd61iRFFBT9HVbu8qhu8R0iCdTRqWS-UhjEkSJmqGK0F4RusdqmNIKUIvV9E6FTeywnIbplzIfZhyG6bEJNfW4nJvMXYOzN_Ub3oZuNkBkB9dW4gyaQteg7ER9CBNsP9Y_ADAA4nj</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2495401926</pqid></control><display><type>article</type><title>A biotin-avidin-system-based virus-mimicking nanovaccine for tumor immunotherapy</title><source>ScienceDirect Journals (5 years ago - present)</source><creator>Lu, Zhuoxuan ; Zhang, Yanwei ; Wang, Yi ; Tan, Guang-Hong ; Huang, Feng-Ying ; Cao, Rong ; He, Nongyue ; Zhang, Liming</creator><creatorcontrib>Lu, Zhuoxuan ; Zhang, Yanwei ; Wang, Yi ; Tan, Guang-Hong ; Huang, Feng-Ying ; Cao, Rong ; He, Nongyue ; Zhang, Liming</creatorcontrib><description>Virus is a nanosized pathogen and mainly composed of viral protein and nucleic acids. Under the pressure of long-term selection, mammals have gradually evolved effective immune mechanisms to defend themselves against viruses. In addition to recognizing viral proteins, immune system can also respond to viral sequence-specific nucleic acids, including CpG ODN, single- and double- strand RNA, and thereby enhancing the ability to remove infected viruses. Inspired by these immune mechanisms, we have attempted to develop a tracing virus-mimicking nanovaccine for tumor immunotherapy. This nanovaccine mainly consists of nucleic acids (CpG ODN), proteins (including tumor-associated antigen, and neutravidin (nAvidin) as skeleton materials for constructing nanovaccine and carriers for loading tumor-associated antigen and CpG ODN), and the dye molecules for assembling nAvidin to form nanoparticles comparable in size to viruses and tracing the vaccine in vitro and in vivo. The as-prepared nanovaccine efficiently induces the maturation of dendritic cell, the enhancement of antigen cross-presentation ability, and amplification of cytokine production in vitro. Furthermore, in vivo analysis clearly shows that it targets lymph nodes, successfully presents antigens to generate tumor-antigen-specific CD8+ T cells and induces a Th1-biased immune response. Most notably, this virus-mimicking nanovaccine significantly inhibits the growth of antigen-expressed tumor and prolongs the survival time of the antigen-expressed tumor bearing mice. [Display omitted] •Nanovaccine formulation simulates viruses in composition and size.•Nanovaccine has self-tracing capability in vivo and in vitro.•Nanovaccine stimulates DC maturation and promotes antigen presentation.•Nanovaccine targets lymph nodes, stimulates generation of specific CD8+ T cells.•Nanovaccine inhibits tumor growth and prolongs survival of tumor-bearing mice.</description><identifier>ISSN: 0168-3659</identifier><identifier>EISSN: 1873-4995</identifier><identifier>DOI: 10.1016/j.jconrel.2021.02.029</identifier><identifier>PMID: 33647430</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Anti-tumor performance ; Biotin-avidin system ; Fluorescence imaging ; Nanovaccine ; Targeting lymph nodes</subject><ispartof>Journal of controlled release, 2021-04, Vol.332, p.245-259</ispartof><rights>2021 Elsevier B.V.</rights><rights>Copyright © 2021 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-8f54b8d23c358ed6fb1d2944dd09a65c672cda9fa2a939ee39067d6cb8a42a393</citedby><cites>FETCH-LOGICAL-c365t-8f54b8d23c358ed6fb1d2944dd09a65c672cda9fa2a939ee39067d6cb8a42a393</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0168365921001024$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33647430$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lu, Zhuoxuan</creatorcontrib><creatorcontrib>Zhang, Yanwei</creatorcontrib><creatorcontrib>Wang, Yi</creatorcontrib><creatorcontrib>Tan, Guang-Hong</creatorcontrib><creatorcontrib>Huang, Feng-Ying</creatorcontrib><creatorcontrib>Cao, Rong</creatorcontrib><creatorcontrib>He, Nongyue</creatorcontrib><creatorcontrib>Zhang, Liming</creatorcontrib><title>A biotin-avidin-system-based virus-mimicking nanovaccine for tumor immunotherapy</title><title>Journal of controlled release</title><addtitle>J Control Release</addtitle><description>Virus is a nanosized pathogen and mainly composed of viral protein and nucleic acids. Under the pressure of long-term selection, mammals have gradually evolved effective immune mechanisms to defend themselves against viruses. In addition to recognizing viral proteins, immune system can also respond to viral sequence-specific nucleic acids, including CpG ODN, single- and double- strand RNA, and thereby enhancing the ability to remove infected viruses. Inspired by these immune mechanisms, we have attempted to develop a tracing virus-mimicking nanovaccine for tumor immunotherapy. This nanovaccine mainly consists of nucleic acids (CpG ODN), proteins (including tumor-associated antigen, and neutravidin (nAvidin) as skeleton materials for constructing nanovaccine and carriers for loading tumor-associated antigen and CpG ODN), and the dye molecules for assembling nAvidin to form nanoparticles comparable in size to viruses and tracing the vaccine in vitro and in vivo. The as-prepared nanovaccine efficiently induces the maturation of dendritic cell, the enhancement of antigen cross-presentation ability, and amplification of cytokine production in vitro. Furthermore, in vivo analysis clearly shows that it targets lymph nodes, successfully presents antigens to generate tumor-antigen-specific CD8+ T cells and induces a Th1-biased immune response. Most notably, this virus-mimicking nanovaccine significantly inhibits the growth of antigen-expressed tumor and prolongs the survival time of the antigen-expressed tumor bearing mice. [Display omitted] •Nanovaccine formulation simulates viruses in composition and size.•Nanovaccine has self-tracing capability in vivo and in vitro.•Nanovaccine stimulates DC maturation and promotes antigen presentation.•Nanovaccine targets lymph nodes, stimulates generation of specific CD8+ T cells.•Nanovaccine inhibits tumor growth and prolongs survival of tumor-bearing mice.</description><subject>Anti-tumor performance</subject><subject>Biotin-avidin system</subject><subject>Fluorescence imaging</subject><subject>Nanovaccine</subject><subject>Targeting lymph nodes</subject><issn>0168-3659</issn><issn>1873-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqFkMtOwzAQRS0EouXxCaAs2aQ4tuPEK1QhXhISLGBtOfYEXGq72Eml_j2uWtgijeZuzsyduQhdVHhW4YpfL2YLHXyE5YxgUs0wySUO0LRqG1oyIepDNM1cW1Jeiwk6SWmBMa4pa47RhFLOGkbxFL3Oi86GwfpSra3JkjZpAFd2KoEp1jaOqXTWWf1l_UfhlQ9rpbX1UPQhFsPocrfOjT4MnxDVanOGjnq1THC-11P0fn_3dvtYPr88PN3On0udDxrKtq9Z1xpCNa1bMLzvKkMEY8ZgoXiteUO0UaJXRAkqAKjAvDFcd61iRFFBT9HVbu8qhu8R0iCdTRqWS-UhjEkSJmqGK0F4RusdqmNIKUIvV9E6FTeywnIbplzIfZhyG6bEJNfW4nJvMXYOzN_Ub3oZuNkBkB9dW4gyaQteg7ER9CBNsP9Y_ADAA4nj</recordid><startdate>20210410</startdate><enddate>20210410</enddate><creator>Lu, Zhuoxuan</creator><creator>Zhang, Yanwei</creator><creator>Wang, Yi</creator><creator>Tan, Guang-Hong</creator><creator>Huang, Feng-Ying</creator><creator>Cao, Rong</creator><creator>He, Nongyue</creator><creator>Zhang, Liming</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20210410</creationdate><title>A biotin-avidin-system-based virus-mimicking nanovaccine for tumor immunotherapy</title><author>Lu, Zhuoxuan ; Zhang, Yanwei ; Wang, Yi ; Tan, Guang-Hong ; Huang, Feng-Ying ; Cao, Rong ; He, Nongyue ; Zhang, Liming</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-8f54b8d23c358ed6fb1d2944dd09a65c672cda9fa2a939ee39067d6cb8a42a393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Anti-tumor performance</topic><topic>Biotin-avidin system</topic><topic>Fluorescence imaging</topic><topic>Nanovaccine</topic><topic>Targeting lymph nodes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lu, Zhuoxuan</creatorcontrib><creatorcontrib>Zhang, Yanwei</creatorcontrib><creatorcontrib>Wang, Yi</creatorcontrib><creatorcontrib>Tan, Guang-Hong</creatorcontrib><creatorcontrib>Huang, Feng-Ying</creatorcontrib><creatorcontrib>Cao, Rong</creatorcontrib><creatorcontrib>He, Nongyue</creatorcontrib><creatorcontrib>Zhang, Liming</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of controlled release</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lu, Zhuoxuan</au><au>Zhang, Yanwei</au><au>Wang, Yi</au><au>Tan, Guang-Hong</au><au>Huang, Feng-Ying</au><au>Cao, Rong</au><au>He, Nongyue</au><au>Zhang, Liming</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A biotin-avidin-system-based virus-mimicking nanovaccine for tumor immunotherapy</atitle><jtitle>Journal of controlled release</jtitle><addtitle>J Control Release</addtitle><date>2021-04-10</date><risdate>2021</risdate><volume>332</volume><spage>245</spage><epage>259</epage><pages>245-259</pages><issn>0168-3659</issn><eissn>1873-4995</eissn><abstract>Virus is a nanosized pathogen and mainly composed of viral protein and nucleic acids. Under the pressure of long-term selection, mammals have gradually evolved effective immune mechanisms to defend themselves against viruses. In addition to recognizing viral proteins, immune system can also respond to viral sequence-specific nucleic acids, including CpG ODN, single- and double- strand RNA, and thereby enhancing the ability to remove infected viruses. Inspired by these immune mechanisms, we have attempted to develop a tracing virus-mimicking nanovaccine for tumor immunotherapy. This nanovaccine mainly consists of nucleic acids (CpG ODN), proteins (including tumor-associated antigen, and neutravidin (nAvidin) as skeleton materials for constructing nanovaccine and carriers for loading tumor-associated antigen and CpG ODN), and the dye molecules for assembling nAvidin to form nanoparticles comparable in size to viruses and tracing the vaccine in vitro and in vivo. The as-prepared nanovaccine efficiently induces the maturation of dendritic cell, the enhancement of antigen cross-presentation ability, and amplification of cytokine production in vitro. Furthermore, in vivo analysis clearly shows that it targets lymph nodes, successfully presents antigens to generate tumor-antigen-specific CD8+ T cells and induces a Th1-biased immune response. Most notably, this virus-mimicking nanovaccine significantly inhibits the growth of antigen-expressed tumor and prolongs the survival time of the antigen-expressed tumor bearing mice. [Display omitted] •Nanovaccine formulation simulates viruses in composition and size.•Nanovaccine has self-tracing capability in vivo and in vitro.•Nanovaccine stimulates DC maturation and promotes antigen presentation.•Nanovaccine targets lymph nodes, stimulates generation of specific CD8+ T cells.•Nanovaccine inhibits tumor growth and prolongs survival of tumor-bearing mice.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>33647430</pmid><doi>10.1016/j.jconrel.2021.02.029</doi><tpages>15</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0168-3659
ispartof Journal of controlled release, 2021-04, Vol.332, p.245-259
issn 0168-3659
1873-4995
language eng
recordid cdi_proquest_miscellaneous_2495401926
source ScienceDirect Journals (5 years ago - present)
subjects Anti-tumor performance
Biotin-avidin system
Fluorescence imaging
Nanovaccine
Targeting lymph nodes
title A biotin-avidin-system-based virus-mimicking nanovaccine for tumor immunotherapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T03%3A52%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20biotin-avidin-system-based%20virus-mimicking%20nanovaccine%20for%20tumor%20immunotherapy&rft.jtitle=Journal%20of%20controlled%20release&rft.au=Lu,%20Zhuoxuan&rft.date=2021-04-10&rft.volume=332&rft.spage=245&rft.epage=259&rft.pages=245-259&rft.issn=0168-3659&rft.eissn=1873-4995&rft_id=info:doi/10.1016/j.jconrel.2021.02.029&rft_dat=%3Cproquest_cross%3E2495401926%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2495401926&rft_id=info:pmid/33647430&rft_els_id=S0168365921001024&rfr_iscdi=true